Altium Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Altium Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-65,000	Closed	-$2.31M	–	77
2023 Q4	$2.31M	Sell	65,000 -197,000	-75%	-$6.04M	1.57%	20
2023 Q3	$7.79M	Buy	262,000 +127,000	+94%	+$2.62M	4.06%	10
2023 Q2	$2.43M	Buy	135,000 +35,000	+35%	+$698K	1.84%	22
2023 Q1	$1.61M	Buy	+100,000	New	+$1.85M	0.89%	42
2022 Q2	–	Sell	-204,000	Closed	-$4.48M	–	131
2022 Q1	$4.48M	Sell	204,000 -127,000	-38%	-$2.57M	1.5%	25
2021 Q4	$9.4M	Buy	331,000 +138,000	+72%	+$3.4M	2.59%	5
2021 Q3	$4.06M	Sell	193,000 -340,033	-64%	-$7.11M	1.07%	38
2021 Q2	$10M	Buy	533,033 +171,103	+47%	+$3.01M	2.33%	4
2021 Q1	$5.53M	Hold	361,930	–	–	1.54%	14
2020 Q4	$5.11M	Buy	+361,930	New	+$5.04M	1.91%	11

Other funds holding CRNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Altium Capital Management's CRNX Position: Q1 2024 in Review

Altium Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2024, closing a stake of 65,000 shares — an estimated $2.31M sold.

Altium Capital Management first reported a position in CRNX in Q4 2020 and held it in 10 quarters. The position peaked at $10M in Q2 2021. 203 funds tracked by Wall St. Rank hold CRNX as of Q1 2024.

Altium Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Altium Capital Management sold 65,000 Crinetics Pharmaceuticals shares in Q1 2024, an estimated $2.31M.
Altium Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2020 and held it in 10 quarters.
Altium Capital Management's Crinetics Pharmaceuticals position peaked at $10M in Q2 2021.
203 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2024.

Based on Altium Capital Management's 13F filing for Q1 2024, filed 15 May 2024.